1. Home
  2. PGEN vs DCTH Comparison

PGEN vs DCTH Comparison

Compare PGEN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • DCTH
  • Stock Information
  • Founded
  • PGEN 1998
  • DCTH 1988
  • Country
  • PGEN United States
  • DCTH United States
  • Employees
  • PGEN N/A
  • DCTH N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • DCTH Medical/Dental Instruments
  • Sector
  • PGEN Health Care
  • DCTH Health Care
  • Exchange
  • PGEN Nasdaq
  • DCTH Nasdaq
  • Market Cap
  • PGEN 493.0M
  • DCTH 388.3M
  • IPO Year
  • PGEN N/A
  • DCTH N/A
  • Fundamental
  • Price
  • PGEN $3.89
  • DCTH $11.02
  • Analyst Decision
  • PGEN Buy
  • DCTH Strong Buy
  • Analyst Count
  • PGEN 5
  • DCTH 4
  • Target Price
  • PGEN $7.50
  • DCTH $24.50
  • AVG Volume (30 Days)
  • PGEN 9.8M
  • DCTH 505.0K
  • Earning Date
  • PGEN 11-13-2025
  • DCTH 11-07-2025
  • Dividend Yield
  • PGEN N/A
  • DCTH N/A
  • EPS Growth
  • PGEN N/A
  • DCTH N/A
  • EPS
  • PGEN N/A
  • DCTH 0.06
  • Revenue
  • PGEN $4,340,000.00
  • DCTH $70,240,000.00
  • Revenue This Year
  • PGEN $253.63
  • DCTH $159.22
  • Revenue Next Year
  • PGEN $699.64
  • DCTH $42.78
  • P/E Ratio
  • PGEN N/A
  • DCTH $197.14
  • Revenue Growth
  • PGEN N/A
  • DCTH 491.35
  • 52 Week Low
  • PGEN $0.65
  • DCTH $8.08
  • 52 Week High
  • PGEN $5.23
  • DCTH $18.23
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 55.94
  • DCTH 51.47
  • Support Level
  • PGEN $3.47
  • DCTH N/A
  • Resistance Level
  • PGEN $5.23
  • DCTH $11.38
  • Average True Range (ATR)
  • PGEN 0.36
  • DCTH 0.43
  • MACD
  • PGEN -0.16
  • DCTH -0.38
  • Stochastic Oscillator
  • PGEN 23.86
  • DCTH 92.37

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: